In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products. Read More on GB:GSK: GSK NewsMORE Related Stocks Indices ...
Gilead is mounting a challenge against GlaxoSmithKline’s HIV drug, Tivicay, with its rival integrase inhibitor bictegravir. At the same time, GSK’s ViiV HIV unit hit back with data of its own ...
GSK posted a healthy 13% increase in second-quarter sales this morning and raised its forecasts for the year on the back of gains for its cancer and HIV drugs, beating market expectations.
With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...
Zacks.com on MSN5d
Gilead Beats on Q3 Earnings and Sales, Raises Annual OutlookGilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback